Nicholas Boddicker

Has grant

Research Associate

Mayo Clinic
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Open

Genetic Epidemiology of Lymphoma: Risk and Heterogeneity

Open Date: 2026-10-01

Close Date: 2027-09-30

Articles (17)

Year:

2026

Purpose: To determine the relationship between germline pathogenic variants (PV) in cancer predisposition genes and the risk of ductal carcinoma in situ (DCIS). Experimental Design: Germline PV frequencies in breast cancer predisposition genes (ATM, BARD1, BRCA1, BRCA2, CDH1, CHEK2, PALB2, RAD51C, and RAD51D) were compared between DCIS cases and unaffected controls and between DCIS and invasive ductal breast cancer (IDC) cases from a clinical testing cohort (n = 9,887), a population-based cohort (n = 3,876), and the UK Biobank (n = 2,421). The risk of contralateral breast cancer (CBC) for DCIS cases with PV was estimated in the population-based cohort. Results: Germline PV were observed in 6.5% and 4.6% of women with DCIS in the clinical testing and population-based cohorts, respectively. BRCA1, BRCA2, and PALB2 PV frequencies were significantly lower among women with DCIS than those with IDC (clinical cohort: 2.8% vs. 5.7%; population-based cohort: 1.7% vs. 3.7%), whereas the PV frequencies for ATM and CHEK2 were similar. ATM, BRCA1, BRCA2, CHEK2, and PALB2 PV were significantly associated with an increased risk of DCIS (OR > 2.0), but only BRCA2 PV were associated with high risk (OR > 4) in both cohorts. The cumulative incidence of CBC among carriers of PV in high-penetrance genes with DCIS was 23% over 15 years. Conclusions: The enrichment of PV in ATM, BRCA1, BRCA2, CHEK2, and PALB2 among women with DCIS suggests that multigene panel testing may be appropriate for women with DCIS. Elevated risks of CBC in carriers of PV in high-penetrance genes with DCIS confirmed the utility of testing for surgical decision-making.

Year:

2025

Purpose: Germline pathogenic variants (PV) in ATM increase the risk of pancreatic ductal adenocarcinoma (PDAC), but the underlying tumor biology of PDAC associated with germline PV in ATM has not been adequately explored. Experimental Design: Whole-genome, whole-exome, and RNA sequencing were performed on PDAC tumors from 25 germline ATM PV carriers diagnosed at Mayo Clinic between 2007 and 2017. Somatic and copy-number alterations, mutational signatures, transcriptomic subtypes, and the immune landscape were evaluated. Results: High-quality whole-exome and whole-genome sequencing were obtained from 21 and 15 tumors, respectively. Biallelic inactivation of ATM was observed in 87%, KRAS PV in 90%, CDKN2A homozygous loss in 60%, and TP53 alterations in <10% of these tumors. A predominant clock-like mutational signature was present in all samples. Whole-transcriptome analysis identified that the aberrantly differentiated endocrine exocrine subtype accounted for 18% of PDAC and was consistently associated with >5-year overall survival. In addition, a 28-gene expression–based signature associated with overall survival was identified and further validated in The Cancer Genome Atlas cohort. Immune landscape analysis through CODEX identified enriched CD4 T-helper cell/tumor interactions and reduced B7H3-high cell/tumor interactions in ATM PV carriers compared with noncarriers. Conclusions: The observed absence of TP53 PV and enrichment for CDKN2A alterations in ATM tumors, along with differences in the mutational signatures, transcriptomic subtypes and immune landscape, improve our understanding of the mechanistic pathways involved in PDAC development in germline ATM PV carriers and help identify potential targeted therapeutic strategies.

Year:

2025

Monoclonal B-cell lymphocytosis (MBL) and clonal hematopoiesis of indeterminate potential (CHIP) are prevalent clonal precursors associated with increased risk of lymphoid malignancies. However, the relationship between MBL and CHIP and their combined impact on lymphoid malignancy risk remains poorly understood. We screened participants from the Mayo Clinic Biobank to identify MBL using eight-color flow cytometry; CHIP was detected using whole-exome sequencing of whole-blood DNA in 291 genes related to myeloid or lymphoid malignancies. Incident myeloid or lymphoid hematological malignancies were identified using ICD codes and confirmed via medical record review. Logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI). Cox regression was used to estimate hazard ratios (HR). Analyses were adjusted for age and sex. In 10,067 participants, 15% had MBL, and 9% had CHIP. No evidence of an association between MBL and CHIP (OR = 1.00; 95% CI: 0.82–1.20) was observed. With a median follow-up of 5.4 years, 138 participants developed hematological malignancies (94 lymphoid). MBL (HR = 3.48; 95% CI: 2.27–5.34; P < 0.001) and CHIP (HR = 1.89; 95% CI: 1.10–3.27; P = 0.022) were each associated with incident lymphoid malignancy. Compared to individuals with no precursors, the combined presence of MBL and CHIP significantly amplified lymphoma risk (HR = 7.18; 95% CI: 3.33–15.47; P < 0.001), more than doubling the risk among individuals with MBL alone (HR = 3.30; 95% CI: 2.06–5.30; P < 0.001). In contrast, the risk associated with CHIP alone was attenuated and no longer statistically significant (HR = 1.63; 95% CI: 0.77–3.47; P = 0.20). MBL and CHIP are independent hematological precursor conditions. While their combined presence amplifies the risk of lymphoid malignancy, CHIP alone may not be a strong independent risk factor.

Year:

2025

We investigated the prevalence of rare inherited pathogenic variants (PV) in 19 cancer predisposition genes regularly included on multi-gene panel testing based on NCCN guidelines and their association with the risk of lymphoid malignancies (LM) overall and by common lymphoma subtypes and multiple myeloma. The study population included newly diagnosed LM cases ( N = 6990) and unrelated controls ( N = 42,632), excluding individuals with a history of hematologic malignancy. Whole exome sequencing was performed on DNA from whole blood. PV were defined as loss-of-function (i.e., nonsense, frameshift, consensus splice sites) or identified as “pathogenic” or “likely pathogenic” in the ClinVar database. A total of 1816 (3.7%) individuals had a PV across the 19 genes, higher in cases (4.7%) than controls (3.5%). In controls, CHEK2 (1.0%), ATM (0.4%), BRCA2 (0.4%), and BRCA1 (0.3%) had the highest prevalence. ATM (odds ratio [OR] = 1.86, 95% confidence interval [CI]: 1.36–2.49), CHEK2 (OR = 1.74, 95% CI: 1.42–2.13) and TP53 (OR = 9.07, 95% CI: 4.51–18.87) were associated with increased risk of LM overall and were further validated in the UK Biobank. We observed heterogeneity in associations by LM subtype. These results demonstrate that several commonly tested cancer predisposition genes are associated with an increased risk of LM.

Year:

2025

Frequencies of all reported germline CHEK2 variant carriers and carriers of variants concordantly categorized by functional our kinase assays in breast cancer patients and controls in 12 analyzed population datasets.

Year:

2025

Supplementary figures displaying supporting evidence Supplemental Figure 1: Results of IHC Staining for ATM expression. Supplemental Figure 2: Variant Summary from Whole Exome Sequencing Supplemental Figure 3: Oncoprint of Somatic Mutations. Supplemental Figure 4: Circos Plot of Copy Number Changes and Structural Arrangements Supplemental Figure 5: Single Base Substitution Profile. Supplemental Figure 6: Single Base Substitution Profile for each Tumor Evaluated through Whole Exome Sequencing Supplemental Figure 7. Characterization of Single Base Substitution Mutational Signatures in Pancreatic Tumors from Germline ATM Carriers based on Whole Genome Sequencing Supplemental Figure 8: Single Base Substitution Profile for each Tumor Evaluated through Whole Genome Sequencing Supplemental Figure 9: Transcriptomic Subtypes of Pancreatic Ductal Adenocarcinoma in germline ATM carriers based on Non-negative Matrix Factorization. Supplemental Figure 10: Transcriptomic Subtypes of Pancreatic Ductal Adenocarcinoma in germline ATM carriers based on predefined genesets Supplemental Figure 11. Heatmap of Tumor and Immune Cell Interactions for Pancreatic Ductal Adenocarcinoma in ATM Pathogenic Variant Carriers and Non-carriers Supplemental Figure 12: Comparison of Tumor and Immune Cell Interactions between ATM Pathogenic Variant Carriers and Non-Carriers

Year:

2025

Purpose: Germline pathogenic variants (PV) in ATM increase the risk of pancreatic ductal adenocarcinoma (PDAC), but the underlying tumor biology of PDAC associated with germline PV in ATM has not been adequately explored. Experimental Design: Whole-genome, whole-exome, and RNA sequencing were performed on PDAC tumors from 25 germline ATM PV carriers diagnosed at Mayo Clinic between 2007 and 2017. Somatic and copy-number alterations, mutational signatures, transcriptomic subtypes, and the immune landscape were evaluated. Results: High-quality whole-exome and whole-genome sequencing were obtained from 21 and 15 tumors, respectively. Biallelic inactivation of ATM was observed in 87%, KRAS PV in 90%, CDKN2A homozygous loss in 60%, and TP53 alterations in 5-year overall survival. In addition, a 28-gene expression–based signature associated with overall survival was identified and further validated in The Cancer Genome Atlas cohort. Immune landscape analysis through CODEX identified enriched CD4 T-helper cell/tumor interactions and reduced B7H3-high cell/tumor interactions in ATM PV carriers compared with noncarriers. Conclusions: The observed absence of TP53 PV and enrichment for CDKN2A alterations in ATM tumors, along with differences in the mutational signatures, transcriptomic subtypes and immune landscape, improve our understanding of the mechanistic pathways involved in PDAC development in germline ATM PV carriers and help identify potential targeted therapeutic strategies.

Year:

2025

Purpose: To determine the relationship between germline pathogenic variants (PV) in cancer predisposition genes and the risk of ductal carcinoma in situ (DCIS). Experimental Design: Germline PV frequencies in breast cancer predisposition genes ( ATM , BARD1 , BRCA1 , BRCA2 , CDH1 , CHEK2 , PALB2 , RAD51C , and RAD51D ) were compared between DCIS cases and unaffected controls and between DCIS and invasive ductal breast cancer (IDC) cases from a clinical testing cohort ( n = 9,887), a population-based cohort ( n = 3,876), and the UK Biobank ( n = 2,421). The risk of contralateral breast cancer (CBC) for DCIS cases with PV was estimated in the population-based cohort. Results: Germline PV were observed in 6.5% and 4.6% of women with DCIS in the clinical testing and population-based cohorts, respectively. BRCA1 , BRCA2 , and PALB2 PV frequencies were significantly lower among women with DCIS than those with IDC (clinical cohort: 2.8% vs. 5.7%; population-based cohort: 1.7% vs. 3.7%), whereas the PV frequencies for ATM and CHEK2 were similar. ATM , BRCA1 , BRCA2 , CHEK2 , and PALB2 PV were significantly associated with an increased risk of DCIS (OR > 2.0), but only BRCA2 PV were associated with high risk (OR > 4) in both cohorts. The cumulative incidence of CBC among carriers of PV in high-penetrance genes with DCIS was 23% over 15 years. Conclusions: The enrichment of PV in ATM , BRCA1 , BRCA2 , CHEK2 , and PALB2 among women with DCIS suggests that multigene panel testing may be appropriate for women with DCIS. Elevated risks of CBC in carriers of PV in high-penetrance genes with DCIS confirmed the utility of testing for surgical decision-making.

Year:

2025

Pathogenic protein-truncating variants of RAD51C , which plays an integral role in promoting DNA damage repair, increase the risk of breast and ovarian cancer. A large number of RAD51C missense variants of uncertain significance (VUS) have been identified, but the effects of the majority of these variants on RAD51C function and cancer predisposition have not been established. Here, analysis of 173 missense variants by a homology-directed repair (HDR) assay in reconstituted RAD51C −/− cells identified 30 nonfunctional (deleterious) variants, including 18 in a hotspot within the ATP-binding region. The deleterious variants conferred sensitivity to cisplatin and olaparib and disrupted formation of RAD51C/XRCC3 and RAD51B/RAD51C/RAD51D/XRCC2 complexes. Computational analysis indicated the deleterious variant effects were consistent with structural effects on ATP-binding to RAD51C. A subset of the variants displayed similar effects on RAD51C activity in reconstituted human RAD51C -depleted cancer cells. Case–control association studies of deleterious variants in women with breast and ovarian cancer and noncancer controls showed associations with moderate breast cancer risk [OR, 3.92; 95% confidence interval (95% CI), 2.18–7.59] and high ovarian cancer risk (OR, 14.8; 95% CI, 7.71–30.36), similar to protein-truncating variants. This functional data supports the clinical classification of inactivating RAD51C missense variants as pathogenic or likely pathogenic, which may improve the clinical management of variant carriers. Significance: Functional analysis of the impact of a large number of missense variants on RAD51C function provides insight into RAD51C activity and information for classification of the cancer relevance of RAD51C variants.

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Collaborators (70)

Jean Yves Masson

Full Professor

Université Laval Faculté de médecine

CANADA
View details

James Cerhan

Professor of Epidemiology

Mayo Clinic Rochester

UNITED STATES
View details

Tomáš Zima

Head of Institute

Charles University and General University Hospital in Prague, First Faculty of Medicine

CZECH REPUBLIC
View details

Kathleen Claes

Full professor

Ghent University Hospital

BELGIUM
View details

Giuseppe Matullo

-

ITALY
View details

Lisa Wiesmüller

Professor

Ulm University

GERMANY
View details

Christopher A. Haiman

University of Southern California

UNITED STATES
View details

Christine Ambrosone

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Eric Hahnen

-

GERMANY
View details

Susan Domchek

Professor, Clinician-Educator

University of Pennsylvania

UNITED STATES
View details

Sara Lindström

University of Washington

UNITED STATES
View details

Maria Rossing

Associate Clinical Professor

Copenhagen University Hospital

DENMARK
View details

Marco Montagna

Istituto Oncologico Veneto

ITALY
View details

Katherine Nathanson

Professor

University of Pennsylvania

UNITED STATES
View details

Jacques Simard

Full Professor

Laval University

CANADA
View details

Nicoletta Resta

Full Professor Medical Genetics

University of Bari Aldo Moro

ITALY
View details

Song Yao

Professor

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Maria Piane

Sapienza University of Rome

ITALY
View details

Sara González

Institut Català d'Oncologia

SPAIN
View details

FEI CHEN

Assistant Professor

University of Southern California

UNITED STATES
View details

Katie O'Brien

Staff Scientist

National Institute of Environmental Health Sciences

UNITED STATES
View details

A Heather Eliassen

Professor

Harvard University

UNITED STATES
View details

Irene Ong

Associate Professor

University of Wisconsin-Madison

UNITED STATES
View details

Alexandra Martins

INSERM

FRANCE
View details

Dale Sandler

Branch Chief

National Institute of Environmental Health Sciences

UNITED STATES
View details

Julie R Palmer

Boston University School of Medicine

UNITED STATES
View details

Clarice Weinberg

Principal Investigator

National Institute of Environmental Health Sciences

UNITED STATES
View details

Alexander E Volk

-

GERMANY
View details

Daniel D. Billadeau

-

UNITED STATES
View details

gaofeng cui

Assistant professor

Mayo Clinic

UNITED STATES
View details

Peter Kraft

Professor

Harvard T.H. Chan School of Public Health

UNITED STATES
View details

Kari Rabe

Assistant Professor of Biostatistics

Mayo Clinic

UNITED STATES
View details

Adrian V. Lee

University of Pittsburgh

UNITED STATES
View details

Siddhartha Yadav

Associate Professor of Oncology

Mayo Clinic

UNITED STATES
View details

Rosalie Griffin

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Mariarosaria Calvello

European Institute of Oncology

ITALY
View details

anna coppa

Sapienza University of Rome

ITALY
View details

Allison DePersia

NorthShore University HealthSystem

UNITED STATES
View details

Paul James

Head of Adult Genetics

The Royal Melbourne Hospital Royal Park Campus

AUSTRALIA
View details

Florentia Fostira

National Centre for Scientific Research-Demokritos

GREECE
View details

Paolo Radice

Head of Reserach Unit

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Robert McWilliams

Mayo Clinic Minnesota

UNITED STATES
View details

Maria Elena. Martinez

University of California

UNITED STATES
View details

Marketa Janatova

Assistanf Professor and researcher

Přírodovědecká Fakulta, Univerzita Karlova

CZECH REPUBLIC
View details

Yuan-Ping Pang

Professor of Biophysics and Pharmacology

Mayo Clinic

UNITED STATES
View details

Gareth Evans

The University of Manchester

UNITED KINGDOM
View details

Esther John

Professor

Stanford University School of Medicine

UNITED STATES
View details

Weng Khong Lim

Assistant Professor

Duke-NUS Medical School

SINGAPORE
View details

Barbara Pasini

Associate Professor of Medical Genetics

Università degli Studi di Torino

ITALY
View details

Ian Campbell

Group Leader

Peter MacCallum Cancer Institute

AUSTRALIA
View details

Stacey J. Winham

Mayo Clinic College of Medicine and Science

UNITED STATES
View details

Jeffrey Weitzel

Professor and Director

University of Kansas Cancer Center

UNITED STATES
View details

Banu K. Arun

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Paul Auer

Professor

Medical College of Wisconsin

UNITED STATES
View details

Hoda Anton-Culver

Professor and Chair

University of California, Irvine

UNITED STATES
View details

Maegan Roberts

Assistant Professor

Ohio State University

UNITED STATES
View details

Alvaro Monteiro

Senior Member - Full Professor

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Corinna Ernst

Hannover Medical School

GERMANY
View details

Steven Hart

Mayo Clinic

UNITED STATES
View details

Allison W Kurian

Professor

Stanford University School of Medicine

UNITED STATES
View details

Kathryn Ruddy

Professor

Mayo Clinic

UNITED STATES
View details

Lidia Feliubadaló

Institut Català d'Oncologia

SPAIN
View details

Koichi Matsuda

University of Tokyo

JAPAN
View details

Kimberly A. Bertrand

Associate Professor of Medicine

Boston University

UNITED STATES
View details

Joanne Ngeow

Head

Nanyang Technological University (NTU)

SINGAPORE
View details

Eric Polley

Associate Professor

University of Chicago

UNITED STATES
View details

Zdenek Kleibl

Laboratory of oncogenetics (head)

Charles University, First Faculty of Medicine

CZECH REPUBLIC
View details

Amanda Toland

Ohio State University

UNITED STATES
View details

Argyrios Ziogas

Professor

University of California, Irvine

UNITED STATES
View details

Laura Cortesi

University of Modena and Reggio Emilia

ITALY
View details